4.3 Article

Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study

Journal

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/2048872618777819

Keywords

Acute coronary syndrome; diabetes; hyperglycaemia

Funding

  1. Swiss National Science Foundation [SPUM 33CM30-124112, SPUM 33CM30-140336, 32473B-163271, SNSF 320030-150025]
  2. Geneva University Hospitals
  3. Swiss Heart Foundation
  4. de Reuter Foundation
  5. Gerbex-Bourget Foundation
  6. Gustave-Prevot and Schmidheiny Foundation
  7. Roche Diagnostics
  8. Eli Lilly
  9. AstraZeneca
  10. Medtronic
  11. Merck Sharpe and Dome
  12. SanofiAventis
  13. St Jude Medical
  14. Zurich Heart House Foundation for Cardiovascular Research, Zurich, Switzerland

Ask authors/readers for more resources

Background: Controversy remains regarding the prevalence of hyperglycaemia in non-diabetic patients hospitalised with acute coronary syndrome and its prognostic value for long-term outcomes. Methods and results: We evaluated the prevalence of hyperglycaemia (defined as fasting glycaemia > 10 mmol/l) among patients with no known diabetes at the time of enrolment in the prospective Special Program University Medicine-Acute Coronary Syndromes cohort, as well as its impact on all-cause death, myocardial infarction, stroke and incidence of diabetes at one year. Among 3858 acute coronary syndrome patients enrolled between December 2009-December 2014, 709 (18.4%) had known diabetes, while 112 (3.6%) of non-diabetic patients had hyperglycaemia at admission. Compared with non-hyperglycaemic patients, hyperglycaemic individuals were more likely to present with ST-elevation myocardial infarction and acute heart failure. At discharge, hyperglycaemic patients were more frequently treated with glucose-lowering agents (8.9% vs 0.66%, p<0.001). At one-year, adjudicated all-cause death was significantly higher in non-diabetic patients presenting with hyperglycaemia compared with patients with no hyperglycaemia (5.4% vs 2.2%, p=0.041) and hyperglycaemia was a significant predictor of one-year mortality (adjusted hazard ratio 2.39, 95% confidence interval 1.03-5.56). Among patients with hyperglycaemia, 9.8% had developed diabetes at one-year, while the corresponding proportion among patients without hyperglycaemia was 1.8% (p<0.001). In multivariate analysis, hyperglycaemia at presentation predicted the onset of treated diabetes at one-year (odds ratio 4.15, 95% confidence interval 1.59-10.86; p=0.004). Conclusion: Among non-diabetic patients hospitalised with acute coronary syndrome, a fasting hyperglycaemia of > 10 mmol/l predicted one-year mortality and was associated with a four-fold increased risk of developing diabetes at one year.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available